Matito, A.Escribese, M. M.Longo, N.Mayorga, C.Luengo-Sanchez, O.Perez-Gordo, M.Matheu, VLabrador-Horrillo, M.Pascal, M.Seoane-Reula, M. E.Soc Espanola Alergologia & Inmunol2025-01-072025-01-072021-01-011018-9068https://hdl.handle.net/10668/24473The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria: (1) typical clinical signs and symptoms of acute, recurrent (episodic), and systemic mast cell activation (MCA); (2) increase in tryptase level to >20% + 2 ng/mL within 1-4 hours after onset of the acute crisis; and (3) response of MCA symptoms to antimediator therapy. Classification of MCAS requires highly sensitive and specific methodological approaches for the assessment of clonal bone marrow mast cells at low frequencies. The Spanish Network on Mastocytosis score has been used successfully as a predictive model for selecting MCAS candidates for bone marrow studies based on a high probability of an underlying clonal mast cell disorder. In this article, we propose a diagnostic algorithm and focus on the practical evaluation and management of patients with suspected MCAS.enAnaphylaxis Antimediator therapy Mast cell activation syndrome Mast cell mediator release-related symptoms TryptaseIndolent systemic mastocytosisEuropean competence networkSerum tryptasePeripheral-bloodVenom immunotherapyBone-marrowHuman skinKit d816vAnaphylaxisDisordersClinical Approach to Mast Cell Activation Syndrome: A Practical Overviewreview33541851open access10.18176/jiaci.06751698-0808http://www.jiaci.org/revistas/vol31issue6_1.pdf734405000001